WHAT IS CLAIMED IS:

~~1. A composition capable of causing the appearance of IL-12 in plasma, the composition essentially consisting of:~~

~~a foreign antigen;~~

~~at least one Th1 cytokine; and~~

~~a DC maturation molecule.~~

~~2. The composition of claim 1 where the foreign antigen is an alloantigen.~~

~~3. The composition of claim 1 where the Th1 cytokine is one or more of the following: IL-1, IL-2, IL-6, IL-8, IL-15, Interferon-gamma, TNF-alpha, GM-CSF.~~

~~4. The composition of claim 1 where the DC maturation molecule is CD40L and/or FasL.~~

~~5. The composition of claim 2 where the alloantigen is on a living T-cell.~~

~~6. The composition of claim 5 where the T-cells are CD4+ cells or Th1 cells.~~

~~7. The composition of claim 6 where the Th1 cell is activated.~~

~~8. The composition of claim 7 where the Th1 cells are activated by cross-linking CD3 and CD28.~~

~~9. The composition of claim 8 where the activated Th1 cells secrete one or more of the following Th1 cytokines: IL-2, IFN-gamma and GM-CSF.~~

~~10. The composition of claim 9 where the activated Th1 cells express the DC maturation molecule CD40L and/or FasL on their surface.~~

~~11. The composition of claim 1 where the components are immobilized on a surface.~~

~~12. The composition of claim 11 where the surface is biodegradable.~~

~~13. The composition of claim 5 where the living T-cells are packaged in a syringe or flexible container.~~

~~14. The composition of claim 13 where the cells are at a concentration of 1×10^7 cells/ml or greater.~~

~~15. The composition of claim 14 where the cells are suspended in a non-nutrient media.~~

~~16. A method of increasing plasma levels of IL-12 in a patient comprising:~~

~~administering a composition comprising of allogeneic cells wherein at least a portion of the cells are activated T-cells;~~

~~monitoring the level of IL-12 in the patient; and~~

~~readministering the composition if sufficient levels of IL-12 are not detected in the plasma of the patient.~~

~~17. The method of claim 16 wherein the detection of IL-12 is not toxic to the patient.~~

~~18. The method of claim 16 wherein the activated T cells are CD4+ cells.~~

~~19. The method of claim 18 wherein the activated CD4 cells are Th1 cells.~~

~~20. The method of claim 19 wherein the Th1 cells are activated by cross linking CD3 and CD28.~~

~~21. The method of claim 16 wherein administration of the composition increases the level of IFN-gamma in the patient and/or the Th1 response.~~

~~22. The method of claim 16 wherein the level of IL-12 in the plasma of the patient is at least about 5000pg/ml.~~

~~23. A method of treating a patient with a disease comprising:~~

~~administering a composition comprising allogeneic cells wherein at least a portion~~

~~are activated T cells, wherein the T cells are activated by cross linking one or more agents bound to the cell surface moieties on the T cells;~~

~~monitoring the level of IL-12 in the patient's plasma; and~~

~~readministering the composition if IL-12 is not detected in the plasma of the patient.~~

~~24. The method of claim 23 wherein the disease is cancer or is a result of a pathogenic infection.~~

~~25. The method of claim 23 wherein the readministering is repeated until the concentration of the endogenous IL-12 is detectable.~~

~~26. A therapeutic composition for increasing the endogenous levels of IL-12 comprising activated allogeneic T cells wherein administration of the composition leads to detectable levels of endogenous IL-12 in the plasma of a patient without toxicity to the patient.~~

~~27. The composition of claim 26 wherein the patient has cancer or an infectious disease.~~

~~28. The composition of claim 26 wherein the T cells are CD4+ cells.~~

~~29. The composition of claim 26 wherein the T cells are activated by cross linking one or more agents that are bound to the cell surface moieties on the T cells.~~

~~30. The composition of claim 26 wherein the one or more agents are monoclonal antibodies such as anti-CD3 and anti-CD28 monoclonal antibodies.~~

1. A composition comprising between one and six intradermal doses, between one and two intratumoral doses and between five and ten intravenous doses of activated allogeneic Th1 cells

with cross-linking agents that cross-link CD3 and CD28 cell surface moieties, wherein the intradermal doses comprise between 1×10^6 to 1×10^7 cells/ml, the intratumoral doses comprise between 1×10^7 to 1×10^8 cells/ml and the intravenous doses comprise between 1×10^7 to 1×10^9 cells/ml, respectively, wherein the cross-linking agents are immobilized on surface of biodegradable beads and wherein the Th1 cells, the cross-linking agents and the biodegradable beads are suspended in a non-nutrient media.

2. The composition of claim 1, wherein the composition comprises between three and six intradermal doses, between one and two intratumoral doses and between six and nine intravenous doses, respectively.

3. The composition of claim 1 where the activated Th1 cells secrete one or more of the following Th1 cytokines: IL-2, IFN-gamma and GM-CSF.

4. The composition of claim 3 where the activated Th1 cells express DC maturation molecule CD40L and/or FasL on their surface.

5. The composition of claim 1 where the doses of Th1 cells are packaged in a syringe.

6. The composition of claim 1 wherein the cross-linking of CD3 and CD28 is through anti-CD3 and anti-CD28 monoclonal antibodies.